These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6863626)

  • 1. Methotrexate-induced necrolysis.
    Reed KM; Sober AJ
    J Am Acad Dermatol; 1983 May; 8(5):677-9. PubMed ID: 6863626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis.
    Primka EJ; Camisa C
    J Am Acad Dermatol; 1997 May; 36(5 Pt 2):815-8. PubMed ID: 9146556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease.
    Hani N; Casper C; Groth W; Krieg T; Hunzelmann N
    Eur J Dermatol; 2000; 10(7):548-50. PubMed ID: 11056429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Harr T; French LE
    Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
    Boruah PK; Bolesta S; Shetty SM
    Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Stevens-Johnson syndrome and toxic epidermal necrolysis following intake of sulfonamides].
    Aberer W; Stingl G; Wolff K
    Hautarzt; 1982 Sep; 33(9):484-90. PubMed ID: 7174320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist?
    Horcajada-Reales C; Pulido-Pérez A; Suárez-Fernández R
    Actas Dermosifiliogr; 2016; 107(1):23-33. PubMed ID: 26520037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Severe skin reactions. Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema exsudativum multiforme majus and generalized bullous fixed drug exanthema].
    Rzany B; Mockenhaupt M; Baur S; Stocker U; Schöpf E
    Hautarzt; 1993 Aug; 44(8):549-54; quiz 554-6. PubMed ID: 8376113
    [No Abstract]   [Full Text] [Related]  

  • 11. Stevens-Johnson syndrome after erythromycin therapy while deployed at sea.
    Williams DA
    Mil Med; 2000 Aug; 165(8):636-7. PubMed ID: 10957862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aetiology in sixteen cases of toxic epidermal necrolysis and Stevens-Johnson syndrome admitted within eight months in a teaching hospital.
    Yeung CK; Ma SY; Hon C; Peiris M; Chan HH
    Acta Derm Venereol; 2003; 83(3):179-82. PubMed ID: 12816151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome.
    Chattopadhyay P; Sarma N
    Singapore Med J; 2011 Feb; 52(2):e31-4. PubMed ID: 21373727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stevens-Johnson Syndrome: A Challenging Diagnosis.
    Davis WD; Schafer PA
    Adv Emerg Nurs J; 2018; 40(3):176-182. PubMed ID: 30059372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications.
    Rotunda A; Hirsch RJ; Scheinfeld N; Weinberg JM
    Acta Derm Venereol; 2003; 83(1):1-9. PubMed ID: 12636014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
    Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stevens-Johnson syndrome/toxic epidermal necrolysis].
    Watanabe H
    Nihon Rinsho; 2012 Aug; 70 Suppl 6():492-7. PubMed ID: 23156557
    [No Abstract]   [Full Text] [Related]  

  • 18. Methotrexate related cutaneous adverse drug reactions: a systematic literature review.
    Zuber M; Harikrishna ; Vidhyashree ; Chhabra M; Venkataraman R; Kumar S; Rashid M
    J Basic Clin Physiol Pharmacol; 2022 Sep; 33(5):549-565. PubMed ID: 34706401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective.
    Gupta LK; Martin AM; Agarwal N; D'Souza P; Das S; Kumar R; Pande S; Das NK; Kumaresan M; Kumar P; Garg A; Singh S
    Indian J Dermatol Venereol Leprol; 2016; 82(6):603-625. PubMed ID: 27716721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
    Ririe MR; Blaylock RC; Morris SE; Jung JY
    J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.